世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

がん幹細胞の市場シェア、規模、動向分析レポート:作用機序別(幹細胞ベースのがん治療、標的CSC)、がん形態別(乳がん、膀胱がん)、地域別、セグメント別予測、2023年~2030年


Cancer Stem Cells Market Share, Size & Trends Analysis Report By Mode Of Action (Stem Cell based Cancer Therapy, Targeted CSCs), By Cancer Forms (Breast Cancer, Bladder Cancer), By Region, And Segment Forecasts, 2023 - 2030

がん幹細胞市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の癌幹細胞市場規模は2030年までに31億米ドルに達し、予測期間中の年平均成長率は12.09%で拡大すると予測されている。幹細... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年10月4日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
200 英語

本レポートは受注生産のため、ご納品のお時間をいただく場合がございます。


 

サマリー

がん幹細胞市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の癌幹細胞市場規模は2030年までに31億米ドルに達し、予測期間中の年平均成長率は12.09%で拡大すると予測されている。幹細胞を用いたがん治療は規制や倫理的な課題に直面しているが、市場は世界的に拡大している。幹細胞に対する認識が高まるにつれ、幹細胞を用いた効果的かつ新規の治療法開発のための研究開発も着実に成長している。

さらに、がん幹細胞(CSC)に関する研究発表の数も増加の一途をたどっている。これらの研究は、医療関係者がCSCsの生物学とそのシグナル伝達経路に関する洞察を得るのに役立っている。このことは、同市場に大きな成長の可能性をもたらすと期待されている。

さらに、実験的アプローチ、特にin vitroアッセイシステムの改善により、科学者は腫瘍内の異なる細胞タイプとその微小環境との関係を確立できるようになった。このことは、腫瘍の成長を抑制し、臨床転帰を改善するために、CSCsとそれに関連する重要な経路に対する幅広い治療ポートフォリオの開発につながっている。

癌幹細胞市場レポートハイライト

- 栄養補助食品は、2022年の売上高シェアで60%を占め、市場を支配している。これは、栄養補助食品における消費者の嗜好が、化学ベースの成分からオーガニックやハーブの成分へと変化しているためである。

- 電子商取引の普及とオンラインで製品を提供するプレイヤーの増加により、オンラインストアは予測期間中最も急成長する流通チャネルになると予想される。

- 北米がカンナビジオール消費者向け健康製品の癌幹細胞市場を支配し、2022年の売上高シェアは約70%。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Mode of action
1.1.2. Cancer forms
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Mode of action
2.2.2. Cancer forms
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Cancer Stem Cells Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.5. Cancer Stem Cells Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic Landscape
Chapter 4. Cancer Stem Cells: Mode of Action Estimates & Trend Analysis
4.1. Cancer Stem Cells Market: Key Takeaways
4.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Targeted Cancerous Stem Cells (CSCs)
4.3.1. Targeted cancerous stem cells market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1. By anti-cancer stem cell therapeutics
4.3.1.1.1. By anti-cancer stem cell therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1. Pathway inhibitors
4.3.1.1.1.1.1. Pathway inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.1. WNT signaling pathway
4.3.1.1.1.1.1.1.1. WNT signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.2. Hedgehog signaling pathway
4.3.1.1.1.1.1.2.1. Hedgehog signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.3. Notch signaling pathway
4.3.1.1.1.1.1.3.1. Notch signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.4. Others
4.3.1.1.1.1.1.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.2. Surface marker-based
4.3.1.1.1.2.1. Surface marker-based market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.3. Immuno-evasion & targeting tumor microenvironment
4.3.1.1.1.3.1. Immuno-evasion & targeting tumor microenvironment market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.4. Nanoparticle-based therapies
4.3.1.1.1.4.1. Nanoparticle-based therapies market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.5. Others
4.3.1.1.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2. By-products
4.3.1.2.1. By products market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.1. Cell culturing
4.3.1.2.1.1.1. Cell culturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.2. Cell Separation
4.3.1.2.1.2.1. Cell separation market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.3. Cell Analysis
4.3.1.2.1.3.1. Cell analysis market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.4. Molecular analysis
4.3.1.2.1.4.1. Molecular analysis market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.5. Others
4.3.1.2.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Stem Cell-based Cancer Therapy
4.4.1. Stem cell-based cancer therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.1. Autologous stem cell transplant
4.4.1.1.1. Autologous stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2. Allogeneic stem cell transplant
4.4.1.2.1. Allogeneic stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Cancer Stem Cells: Cancer Forms Estimates & Trend Analysis
5.1. Cancer Stem Cells Market: Key Takeaways
5.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Breast Cancer
5.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Blood Cancer
5.4.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Lung Cancer
5.5.1. Lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Brain Cancer
5.6.1. Brain cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Colorectal Cancer
5.7.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Pancreatic Cancer
5.8.1. Pancreatic cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Bladder Cancer
5.9.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Liver Cancer
5.10.1. Liver cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Other Cancer
5.11.1. Other cancer market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Cancer Stem Cells Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Cancer Stem Cells Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Thermo Fisher Scientific, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product Benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AbbVie, Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Merck KGaA
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Bionomics
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Lonza
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Stemline Therapeutics, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Miltenyi Biotec
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. PromoCell GmbH
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. MacroGenics, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. FUJIFILM Irvine Scientific
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. STEMCELL Technologies.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Sino Biological, Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Lineage Cell Therapeutics, Inc.
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives

 

ページTOPに戻る


 

Summary

Cancer Stem Cells Market Growth & Trends

The global cancer stem cells market size is expected to reach USD 3.1 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 12.09% during the forecast period. Although stem cell-based cancer treatment is facing regulatory and ethical challenges, the market is growing worldwide. With increasing awareness about these cells, there is steady growth in the R&D for the development of effective and novel treatment methods based on stem cells.

Furthermore, continuous rise has been observed in the number of research studies on cancer stem cells (CSCs) being published. These studies have helped healthcare professionals gain insights into CSCs biology and their signaling pathways. This is expected to create tremendous growth prospects for the market.

Furthermore, improvements in experimental approaches, in particular, in vitro assay systems have enabled scientists to establish relationship between different cell types in a tumor and their microenvironment. This has led to development of a broad therapeutic portfolio for CSCs and their associated key pathways for restricting growth of the tumor and providing improved clinical outcome.

Cancer Stem Cells Market Report Highlights

• Nutraceuticals dominated the market in 2022 with a revenue share of 60%, owing to the changing consumer preferences from chemical-based ingredients to organic and herbal ingredients in dietary supplements

• Online stores is anticipated to be the fastest-growing distribution channel segment over the forecast period, owing to the increase in penetration of e-commerce and the rising number of players offering their products online

• North America dominated the Cancer Stem Cells market for cannabidiol consumer health products, with a revenue share of around 70% in 2022.



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Mode of action
1.1.2. Cancer forms
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Mode of action
2.2.2. Cancer forms
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Cancer Stem Cells Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.5. Cancer Stem Cells Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic Landscape
Chapter 4. Cancer Stem Cells: Mode of Action Estimates & Trend Analysis
4.1. Cancer Stem Cells Market: Key Takeaways
4.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Targeted Cancerous Stem Cells (CSCs)
4.3.1. Targeted cancerous stem cells market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1. By anti-cancer stem cell therapeutics
4.3.1.1.1. By anti-cancer stem cell therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1. Pathway inhibitors
4.3.1.1.1.1.1. Pathway inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.1. WNT signaling pathway
4.3.1.1.1.1.1.1.1. WNT signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.2. Hedgehog signaling pathway
4.3.1.1.1.1.1.2.1. Hedgehog signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.3. Notch signaling pathway
4.3.1.1.1.1.1.3.1. Notch signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.1.1.4. Others
4.3.1.1.1.1.1.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.2. Surface marker-based
4.3.1.1.1.2.1. Surface marker-based market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.3. Immuno-evasion & targeting tumor microenvironment
4.3.1.1.1.3.1. Immuno-evasion & targeting tumor microenvironment market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.4. Nanoparticle-based therapies
4.3.1.1.1.4.1. Nanoparticle-based therapies market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1.1.5. Others
4.3.1.1.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2. By-products
4.3.1.2.1. By products market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.1. Cell culturing
4.3.1.2.1.1.1. Cell culturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.2. Cell Separation
4.3.1.2.1.2.1. Cell separation market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.3. Cell Analysis
4.3.1.2.1.3.1. Cell analysis market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.4. Molecular analysis
4.3.1.2.1.4.1. Molecular analysis market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2.1.5. Others
4.3.1.2.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Stem Cell-based Cancer Therapy
4.4.1. Stem cell-based cancer therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.1. Autologous stem cell transplant
4.4.1.1.1. Autologous stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2. Allogeneic stem cell transplant
4.4.1.2.1. Allogeneic stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Cancer Stem Cells: Cancer Forms Estimates & Trend Analysis
5.1. Cancer Stem Cells Market: Key Takeaways
5.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Breast Cancer
5.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Blood Cancer
5.4.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Lung Cancer
5.5.1. Lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Brain Cancer
5.6.1. Brain cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Colorectal Cancer
5.7.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Pancreatic Cancer
5.8.1. Pancreatic cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Bladder Cancer
5.9.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Liver Cancer
5.10.1. Liver cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Other Cancer
5.11.1. Other cancer market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Cancer Stem Cells Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Cancer Stem Cells Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Thermo Fisher Scientific, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product Benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AbbVie, Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Merck KGaA
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Bionomics
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Lonza
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Stemline Therapeutics, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Miltenyi Biotec
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. PromoCell GmbH
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. MacroGenics, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. FUJIFILM Irvine Scientific
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. STEMCELL Technologies.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Sino Biological, Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Lineage Cell Therapeutics, Inc.
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

Grand View Research社の生物分野での最新刊レポート

本レポートと同じKEY WORD(action)の最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る